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Abstract Chronic hepatitis C virus (HCV) infection is
characterized by increased rates of apoptotic hepatocytes
and activated caspases have been shown in HCV-infected
patients. GS-9450, a novel caspase-inhibitor has demon-
strated hepatoprotective activity in ﬁbrosis/apoptosis
animal models. This study evaluated the effects of GS-
9450 on peripheral T-cell apoptosis in chronic HCV-
infected patients. As sub study of the GS-US-227-0102, a
double-blind, placebo-controlled phase 2a trial evaluating
the safety and tolerability of GS-9450, apoptosis of
peripheral CD4? and CD8? T-cells was measured using
activated caspase-3, activated caspase-8 and CD95 (Fas).
Blood samples were drawn at baseline, day 14 after therapy
and at 5 weeks off-treatment follow-up in the ﬁrst cohort of
10 mg. In contrast to the placebo-treated patients, GS-9450
caused a median of 46% decrease in ALT-values from
baseline to day 14 in all treated patients (median of
118–64 U/l) rising again to a median of 140 U/l (19%) at
5 weeks off-treatment follow-up. In GS9450-treated
patients, during treatment and follow-up, percentages of
activated caspase-3? and caspase-8 expression tended to
decrease, in contrast to placebo-treated patients. Interest-
ingly, compared to healthy controls, higher percentages of
caspase-3 and caspase-8 positive CD4? and CD8? T-cells
were demonstrated in HCV-infected patients at baseline.
Decreased ALT-values were observed in all HCV-infected
patients during treatment with low dose of the caspase-
inhibitor GS-9450 accompanied by a lower expression of
caspase-3 and -8 on peripheral T-cells. Furthermore, at
baseline percentages of activated caspase-3, activated
caspase-8 and CD95? T-cells were higher in chronic
HCV-infected patients compared to healthy controls.
Keywords Hepatitis C virus  Apoptosis  Caspase-3 
Caspase-8  CD95
Introduction
Persistence of the Hepatitis C Virus (HCV) in the liver
leads to the development of liver ﬁbrosis over the course of
decades [1]. This process of liver ﬁbrosis progression is a
complex interplay between activated T-cells, activated
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Apoptosis or programmed cell death is a physiological
phenomenon that occurs in most organs in the human body
and is a key element in the host defense against viral
pathogens [3]. The main signaling pathway to induce
apoptosis in hepatic diseases and normal healthy livers is
the death receptor pathway consisting of different receptors
of the Tumor Necrosis Factor family being TNF-related
apoptosis-inducing ligand (TRAIL), TNF-alpha and Fas
(CD95/APO-1) [4]. Fas ligand (FasL) is expressed by
natural killer cells and cytotoxic T lymphocytes (CTLs, i.e.
CD8? effector T-cells) and Fas–FasL interaction is the
main effector mechanism of CTLs inducing apoptosis of
virus infected hepatocytes [5, 6]. Recently, in a HCV
genotype 1b transgenic mouse model an increased rate of
apoptosis of peripheral CD4? and CD8? T-cells was
noted when compared to healthy control mice [7]. Fur-
thermore, this was associated with an up-regulation of FasL
on the hepatocytes suggesting that the hepatic microenvi-
ronment, with up-regulation of FasL, promotes increased
T-cell apoptosis and thereby contributes to viral
persistence.
Apoptosis is gradually being more recognized as an
important factor in liver ﬁbrosis development [8–10].
Caspases, proteolytic enzymes belonging to a family of
intracellular cysteine proteases, play an important role in
this apoptotic process. After interaction with the cell sur-
face Fas-receptor, intra-cellular activation of death
domains (FADD) result in proteolytic cleavage pro-cas-
pase-8 into its active form caspase-8 [11]. This process
leads downstream to the cleavage of pro-caspase-3 into its
active form caspase-3, the central protease in the apoptosis
pathway. The role of apoptosis in chronic HCV is currently
not well understood. Liver biopsy studies in patients with
chronic HCV have shown an increased presence of apop-
totic hepatocytes [12, 13]. Moreover, the percentage of
apoptotic hepatocytes, demonstrated immunohistochemi-
cally as caspase-3 positive cells, has been shown to cor-
relate with the amount of liver ﬁbrosis [14, 15].
GS-9450 is an irreversible inhibitor of caspase-8, -9,
and -1 and has demonstrated hepatoprotective activity in
both ﬁbrosis assays and apoptosis animal models
(unpublished). Furthermore, a phase-1 trial dosing GS-
9450 for 14 days in healthy volunteers proved to be safe
and well tolerated [16]. Recently, the results of a phase-2a
study, evaluating the safety and tolerability of GS-9450
have been presented [17]. However, since both a baseline
liver biopsy was not mandatory for entering the phase-2
study and in the previous phase-1 study, the effect of GS-
9450 on the T-cells was not evaluated, it was decided to
analyze the effects of GS-9450 on peripheral T-cell
apoptosis during GS-9450 therapy as a sub study during
the phase-2a study.
Patients and methods
Clinical study
The GS-US-227-0102 was a phase 2a trial evaluating the
safety and tolerability GS-9450, a potent irreversible
inhibitor of caspase-8, -9, and -1. This novel drug is cur-
rently developed by Gilead Inc. (Durham, NC, USA).
Ascending doses of GS-9450 were evaluated in this ran-
domized placebo-controlled study [17]. For the ﬁrst cohort
of 10 mg GS-9450, 8 patients were included from the
Netherlands, 6 receiving GS-9450 and 2 receiving placebo.
Inclusion was based on the presence of a chronic HCV
infection and ALT or AST[1.59 the upper limit of normal
(ULN; in our centre 35 U/l). Furthermore, patients had to
have previously failed conventional anti-HCV therapy,
were unable to tolerate it, or had contraindications for
treatment with (peg)interferon-alfa/ribavirin. Important
exclusion criteria were decompensated liver disease or
evidence of hepatocellular carcinoma (based on liver
biopsy within the previous 2 years), coinfection with hep-
atitis B virus (HBV) or human immunodeﬁciency virus
(HIV) and current or near future pregnancy. A laboratory
sub study of this trial was designed for this ﬁrst cohort,
evaluating the effects of GS-9450 on peripheral T-cells.
PBMC processing
Peripheral blood (approximately 30 ml) was collected at
baseline (i.e. day 0 of the study), at week 2 (i.e. day 14 of
the study) and at week 7 (i.e. 5 weeks off-treatment follow-
up). Within 24 h, peripheral blood mononuclear cells
(PBMC) were isolated using a Ficoll-Hypaque density
gradient centrifugation. Cells were re-suspended in RPMI
1640 (Gibco Life Technologies, Breda, The Netherlands)
to which 20% fetal calf serum and 1% penicillin and
streptomycin were added (hereafter called medium).
Except for the caspase-8 experiment, which were per-
formed on frozen PBMC, all assays were performed on
fresh PBMC. As controls, blood of 5 healthy individuals
(Healthy Controls, HC) was requested from the local blood
bank (screened and negative for hepatitis B, HIV and
hepatitis C).
Selection of apoptosis markers on peripheral T-cells
In vitro analysis of the caspase-inhibitor GS-9450 showed
inhibition of activated caspase-8. Since caspase-3 (i.e. the
main caspase protein in the apoptosis pathway) is a
downstream caspase it was assumed that by inactivating
caspase-8, the expression of caspase-3 would be reduced.
Furthermore, CD95 of Fas is the main receptor initiating
apoptosis in HCV-infected patients and upstream of
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123caspase-8. Therefore, CD95, caspase-3 and -8 were chosen
as markers for the measurement of apoptosis in peripheral
T-cells. Although annexin-V/PI is a well-known assay to
establish apoptosis, we choose to examine those markers
that are directly involved in the working mechanism of
GS9450.
Apoptosis analysis by FACS
PBMC in medium were washed and resuspended in PBA
(phosphate buffered saline containing 0.16% BSA and
0.1% sodium-azide) to a concentration of 2 million PBMC/
ml and divided in aliquots of 200 ll. Cells were incubated
for 15 min at 4C with 2 different sets of antibodies:
(i) against activated caspase-3 (FITC, BD Biosciences, San
Jose ´, CA, USA) and (ii) against activated caspase-8 (FITC,
Biovision, Mountain View, CA, USA) Added to both these
two different sets were antibodies against CD3 (paciﬁc
Blue), CD4 (PECy7, BD), CD8 (APCCy7, eBioscience,
San Diego, USA) and CD95 (PE, BD). Cells for caspase-
expression were washed and permeabilized with permaly-
sis buffer (BD) and stained with antibodies for activated
caspase-3 or activated caspase-8 for 15 min at 4C. After
washing, cells were ﬁxed with Cellﬁx (BD) and at least
200,000 cells were acquired by Fluorescence Activated
Cell Sorting (FACS, LRSII, BD).
Using the FACSDiva software (BD), we constructed a
CD4 PECy7 and CD8 APCCy7 scatter plot, gated CD3?
T-cells, in order to identify all CD3?CD4? and
CD3?CD8? T-cells. Within these populations we gated
on activated caspase-3 and CD95 to obtain the percentage
of caspase or CD95 expressing CD3?CD4? or CD3?
CD8? T-cells.
Statistical analysis
Continuous data are presented as median values [with
interquartile range (IQR)] and analyzed non-parametrically
using a Mann–Whitney U-test for baseline values and a
Friedman test for longitudinal analysis. Categorical vari-
ables are given as numbers of cases (percentage). A
P value B0.05 was considered as statistically signiﬁcant
and all tests used were two-sided. All data were analyzed
using GraphPad Prism (version 5.0 for Windows, Graph-
Pad Software, San Diego, USA).
Results
Eight patients were randomized to receive either 10 mg
GS-9450 (n = 6) or placebo (n = 2). Patient characteris-
tics are given in Table 1 showing that the majority of
patients were male (75%) with a median age of 50 years.
As mandatory for inclusion, all patients had elevated ALT-
values with a median of 118 U/l. Baseline viral loads
varied from 1,500 to 1,350,000 IU/ml with a median of
409,000 IU/ml. Since inclusion of all genotypes was
allowed, 4 patients (50%) were infected with genotype 1, 2
(25%) with genotype 4 and 2 (25%) with genotype 3.
Treatment with either GS-9450 or placebo was generally
well tolerated with fatigue, headache and nausea being the
most reported side-effects.
The efﬁcacy of 10 mg of GS-9450 was studied in a
14-day dosing trial. Irrespective of the allocated treatment
group, ALT-values declined in 7 of 8 study subjects during
the ﬁrst 14 days of the study (Fig. 1a). In patients receiving
GS-9450, median ALT-values dropped from 118 to 64 U/l
(-46%) rising again to 140 U/l (?19%) at week 7 (i.e.
5 weeks of treatment follow-up) (P = 0.006; Friedman
test). In one of the patients receiving placebo ALT-values
did not change during the treatment period. In the other
patient, ALT-values decreased from 178 U/l at baseline to
78 U/l (-56%) at day 14 and further declined to 59 U/l
(-67%) at week 7 while rigorously changing his lifestyle
(i.e. discontinuation of alcohol consumption and loosing
15 kg of body weight). During the 14-day trial HCV viral
loads remained stable within 1 log in all but one patient
(Fig. 1b). This patient experienced a 2.61 Log10 increase in
HCV-RNA during the 14 day treatment period which
declinedbutdidnotreturntobaselinevalueduringfollow-up.
Baseline expression of caspase-3, caspase-8 and CD95
on peripheral T-cells
Since a mouse model has suggested an interaction between
HCV-infected hepatocytes and T-cell apoptosis contribut-
ing to viral persistence and liver biopsies were not per-
formed at baseline, we were interested in the effects of
GS-9450 on peripheral T-cells in chronic HCV patients in
this study. In order to be able to interpret the expression of
activated caspase-3, activated caspase-8 and CD95 by
peripheral T-cells, we ﬁrst analyzed these markers in 5
healthy controls (HC). A representative ﬂow cytometry dot
plot of a healthy control demonstrating both CD4? and
CD8? populations as well as the expression of activated
caspase-3 and CD95 on CD8? T-cells is shown in Fig. 2a.
Furthermore, expression of activated caspase-3 and CD95
is shown on CD8? T-cells of a patient (Fig. 2b). The
median percentage of intra-cellular activated caspase-3
expression in HC was 0.4% (IQR 0.1–1.1) for CD4?
T-cells and 0.1% (IQR 0–0.9) for CD8? T-cells. Com-
pared to these HC, higher rates of activated caspase-3 were
detected in HCV-infected patients in CD4? T-cells
(median 9.7% with IQR 6.2–25.5; P = 0.002) and CD8?
T-cells (median 3.3% with IQR 1.5–8.5; P = 0.01)
(Fig. 3a). Expression of activated caspase-8 by CD8?
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123T-cells was also signiﬁcantly higher in chronic HCV-
patients compared to HC [median 10.3 (IQR 6.5–22.8) and
3.90 (IQR 3.2–7.3); P = 0.02] with a trend towards sig-
niﬁcance for the CD4? T-cells [14.8 (IQR 7.5–41.0) and
6.7 (IQR 6.4–8.0); P = 0.07]. Finally, surface expression
of CD95 on CD4? T-cells was higher in patients compared
to HC [median 67.8% (IQR 54.8–78.9) and 46.4% (IQR
32.3–51.6); P = 0.02] (Fig. 3b). However, this difference
was not signiﬁcant in CD8? T-cells between patients
[median 62.2% (IQR 58.9–70.9)] and HC [median 36%
(IQR 27.6–60); P = 0.10].
Longitudinal analysis of caspase-3 and CD95
expression in peripheral T-cells
Next, we analyzed the expression of activated caspase-3,
activated caspase-8 and CD95 during the 14-day dosing
period. Percentages of activated caspase-3? CD4?
T-cells decreased in all patients (Fig. 4a) during the study
period. In GS9450-treated patients the percentage of
caspase-3? CD4 T-cells went from a median of 16.2 to
6.3 and 9.9 at baseline, week 2 and 5 follow-up respec-
tively (P = 0.05; Friedman). This in contrast to the 2
placebo-treated patients showing no signiﬁcant drop in
caspase-3? CD4 T-cells during the study period. At
5 weeks off-treatment follow-up, it was noted that in the
majority of patients activated caspase-3 expression
returned to baseline values or even increased in the 2
patients receiving placebo during the dosing period.
Activated caspase-3 expression in CD8? T-cells was
more variable during the 14-days on treatment, decreasing
in 4 of 8 patients (50%) and increasing in the others
(Fig. 4b). There was no signiﬁcant difference in caspase-
3? CD8? T-cells changes in both GS9450-treated
patients (P = 0.74) and placebo-treated patients (P =
0.83). Five weeks after discontinuation, expression of
activated caspase-3 by CD8? T-cells returned to baseline
values in most patients.
Table 1 Characteristics of the patients treated with either GS-9450 or placebo
Patient Age
(years)
Sex HCV-RNA
(IU/ml)
Genotype ALAT
(U/l)
Side-effects Treatment
1001 49 Male 438,000 1b 121 Dizziness and nausea 10 mg
1002 56 Female 1,200,000 4a/4c/4d 109 Fatigue, somnolence and feeling hot 10 mg
1003 43 Male 39,000 4a/4c/4d 178 Hyperhidrosis, affect lability, ﬂank pain
and tooth infection
Placebo
1004 51 Female 894,000 3a 209 Headache, palpitations, dry skin, ﬂank pain
and parosmia
10 mg
1005 40 Male 196,000 1a 171 Vomiting, affect lability, nausea, headache,
sore throat, rhinitis and fatigue
10 mg
1006 40 Male 380,000 3a 115 Affect lability 10 mg
1007 54 Male 1,500 1a/1b 65 Headache and gastro-enteritis 10 mg
1008 56 Male 1,350,000 1a 70 Nausea, headache, fatigue and back pain Placebo
Median
(IQR)
50
(51–56)
NA 409,000
(78,250–1,124,000)
NA 118
(80–176)
NA NA
NA not applicable
Fig. 1 Longitudinal analysis of ALT and HCV-RNA during therapy.
Changes (%) in plasma ALT (a) and change in HCV-RNA values
(b) from baseline during the duration of the study. On the y-axis are
the % change in ALT (U/l) and the DHCV-RNA (log10 IU/ml)
depicted. On the x-axis the weeks of the study are shown. Patients
treated with the caspase-inhibitor GS-9450 are represented by the
solid black lines and black dots and those receiving placebo are
represented by the black dotted lines and open squares
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evaluated on frozen PBMC, we investigated the effects of
freezing/thawing on activated caspase-8 expression. Com-
parison of activated caspase-8 expression between frozen
and fresh PBMC in healthy controls did not show signiﬁ-
cant differences between the two methods (P = 0.64;
Wilcoxon signed rank test). Activated caspase-8 expression
in CD4? T-cells decreased in all but one patient, returning
to baseline in 3 patients or declining further in another 4
patients at week 7 (P = 0.74 for GS9450 treated and
P = 1.0 for placebo treated patients; Friedman test)
(Fig. 4c). Similarly, expression of activated caspase-8 by
CD8? T-cells showed a decrease in 5 of 8 patients
returning to baseline in 4 of them (P = 0.57 for GS9450
treated and P = 0.50 for placebo treated patients;
Friedman test) (Fig. 4d). A mostly similar expression of
Fig. 2 Flow cytometry analysis
of caspase-3 and CD95
expression. a Representation of
a scatter plot deﬁning a patient’s
CD4? and CD8? populations
on the left. The middle and right
plots represent expression of
activated caspase-3 and CD95
in a healthy control’s CD8?
T-cells (x-axis). b Flow
cytometry dot plot showing a
longitudinal expression of
activated caspase-3 and CD95
in a chronic HCV-infected
patient treated with the caspase-
inhibitor GS-9450. The upper
row depicts the caspase-3
expression while the lower row
shows the CD95 expression
(y-axis). From left to right, the
study weeks 0, 2 and 7 are
depicted
Fig. 3 Baseline expression of activated caspase-3 and CD95 in
peripheral T-cells. Comparison of activated caspase-3 (a), caspase-8
(b) and CD95 (c) expression on peripheral T-cells between patients in
the GS-9450 study at baseline and healthy controls (HC). On the
y-axis the percentages of either activated caspase-3, caspase-8 or
CD95 are depicted. The black dots represent CD4 T-cells and the
black squares the CD8 T-cells. Of 1 patient FACS analysis of CD8?
T-cells failed resulting in 7 patients being evaluated. CD4? T-cells of
2 HC were unavailable for caspase-8 analysis
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both placebo-treated and GS9450-treated patients demon-
strating that inactivation of activated caspase-8 lowers the
downstream expression of activated caspase-3. This is also
demonstrated by the signiﬁcant correlation between the
expression of activated caspase-3 and activated caspase-8
(Spearman r = 0.40 and P = 0.008) when CD4? and
CD8? T-cells at weeks 0, 2 and 7 were analysed together.
Differences in expression of CD95 by CD4? T-cells
during the study were less pronounced and not signiﬁcant
with 5 patients showing minimal changes while 3 patients
showed a decrease in CD95 expression (Fig. 4e). In CD8?
T-cells CD95 expression decreased in 5 of 8 patients from
baseline to week 2 and even further at week 7. A signiﬁcant
correlation between the expression of activated caspase-3
and CD95 was noted (Spearman r = 0.34 and P = 0.02).
Discussion
In this study we evaluated the effects of the caspase-
inhibitor GS-9450 on peripheral T-cells during a 14-day
treatment period. Although treatment with GS-9450
resulted in lower ALT-values, it did not affect either the
HCV viral load or the peripheral T-cells apoptosis rates.
However, we demonstrate that at baseline, percentages of
activated caspase-3, activated caspase-8 and CD95 T-cells
are higher in chronic HCV-infected patients compared to
healthy controls.
The effect of GS-9450 on lowering the ALT-value was
strong (nearly 50% reduction) suggesting a decrease in
apoptotic hepatocytes and thus prevention of release of
aminotransferase enzymes. In addition, cessation of alco-
hol consumption was a study requirement and might
explain in part the ALT-decrease in these patients. This is
supported by the observation that the ALT-values of one
placebo-treated patient decreased during therapy and even
further declined after placebo-discontinuation at the time
ALT-values in GS-9450 treated patients increased again.
A competitor caspase-inhibitor, of which development
recently has been stopped, showed a similar decline in
ALT-values (in a dose-depended matter) in chronic HCV
patients in both a 14-day and a 12-week dosing trial
[18, 19]. In all these caspase-inhibitor studies an overshoot
of aminotransferase activity occurred after discontinuation
of the drug which might be caused by an abrupt release of
blockade of apoptosis. This could be prevented by tapering
instead of abrupt discontinuation and should be investi-
gated in future studies.
In contrast to the decrease in ALT-values, treatment
with GS-9450 did result only in a slight decrease in
caspase-8 expression on peripheral T-cells. In rats it was
found that the concentration of GS-9450 was about 30-fold
higher in the liver compared to peripheral blood. If this
Fig. 4 Longitudinal analysis of activated caspase-3, caspase-8 and
CD95 expression Longitudinal analysis of CD4? and CD8? T-cells
expressing activated caspase-3 (a, b), caspase-8 (c, d) and CD95
(e, f) during therapy. On the y-axis percentages of either activated
caspase-3, caspase-8 or CD95 are shown and on the x-axis the weeks
of the study are depicted. The black solid lines represent the patients
receiving GS-9450 and the black dotted lines represent those taking
placebo. One patient’s CD8? T-cells at baseline (see Fig. 3) and
another patient’s CD8? T-cells at week 7 were not available for
analysis
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123concentration difference is true for human, than this he-
patoselective effects of GS-9450 could be one explanation
for small effect on caspase-8 expression in peripheral
T-cell. Another possible explanation for this small effect on
caspase-8 expression could be that the dose of 10 mg GS-
9450 was too low to exert a larger effect on peripheral
T-cell apoptosis while maximal concentrations were
reached intra-hepatically. The relatively higher drop in
activated caspase-3 levels could be explained from the
working mechanism of GS9450. By inactivating activated
caspase-8, the percentage of downstream cascadic acti-
vated caspase-3 expression is much more affected.
An interesting observation in this study was the signif-
icant differences in activated caspase-3, activated caspase-
8 and CD95 expression by peripheral T-cells between
chronic HCV patients and healthy controls. This could not
be explained by a difference in T-cell activation markers
(HLA-DR/CD38) or T-cell phenotypes (CD27/CD45RO)
since no difference between HC and HCV-infected patients
could be demonstrated for these T-cell features (data not
shown). The reason for the higher rate of apoptosis in
chronic HCV patients is currently unknown. It has been
shown by Toubi et al. [20] that both spontaneous and
dexamethasone-induced apoptosis was increased in chronic
HCV-infected patients compared to healthy individuals.
They also showed that dexamethasone-induced apoptosis
of peripheral T-cells was correlated with increased ALT-
values and decrease NF-jB levels. Furthermore, experi-
mental HCV murine models have suggested that both HCV
core and non-structural proteins enhance apoptosis of
activated CD4? and CD8? T-cells via up-regulation of
Fas–FasL interaction [7, 21]. This may suggest that HCV is
capable of down-regulating speciﬁc immune responses by
inducing T-cell apoptosis and therefore contributing to
persistence of a chronic HCV infection.
This study has several limitations. First, as staging of
liver ﬁbrosis was not part of the study, correlation between
liver ﬁbrosis and apoptosis-markers could not be per-
formed. This would have been of interest given the earlier
publications demonstrating a relation between intra-hepatic
caspase expression and the degree of ﬁbrosis [14]. When a
correlation between the stage of liver ﬁbrosis and periph-
eral T-cell apoptosis at baseline could be demonstrated,
this might be a valuable marker for evaluation of liver
ﬁbrosis. However, no correlation was shown between
ALT-values and either activated caspase-3, activated
caspase-8 or CD95 expression (data not shown). Further-
more, the number of patients in this study was small pos-
sibly explaining the absence of signiﬁcance in baseline
CD95?CD8? T-cells between HCV-infected patients and
HC. Finally, the caspase-8 analyses were performed on
frozen T-cells. Freezing of cells is known to induce
apoptosis in cells [3, 14]. However, the differences in
activated caspase-8 expression between fresh and frozen
PBMC was limited (data not shown) and longitudinal
changes in expression of activated caspase-3 and activated
caspase-8 was similar. Therefore we think that the effects
of freezing in this study is negligible. However, further
studies of the role of activated caspase-3 and activated
caspase-8 by peripheral T-cells is needed.
In conclusion, the caspase-inhibitor GS-9450 decreased
ALT-values during a 14-day dosing period. Furthermore,
the expression of activated caspase-8 and mainly of acti-
vated caspase-3 by peripheral T-cells decreased during the
treatment period. Moreover, baseline expression of acti-
vated caspase-3, activated caspase-8 and CD95 were found
to be higher in patients with chronic HCV compared to
healthy controls.
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